Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity May 12, 2014
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors May 5, 2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis Apr 7, 2014
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA Mar 4, 2014
